“I am pleased to announce the expansion of the Curis (CRIS) Executive Team with the addition of Dr. Ahmed Hamdy as our Chief Medical Officer. Dr. Hamdy is a well-known and respected leader in the industry and brings a wealth of experience as CMO of Pharmacyclics, CMO and CEO of Acerta, and CEO of Vincerx. We look forward to his contributions to Curis,” said James Dentzer, President and CEO of Curis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRIS:
- Curis’s Strategic Advancements and Promising Outlook in IRAK4 Inhibitor Space Drive Buy Rating
- Curis’s Promising Clinical Developments and Strategic Path to Accelerated Approval Boost Buy Rating
- Curis Inc. Reports Q4 2024 Progress and Financials
- Curis Inc. Earnings Call: Progress Amidst Challenges
- Curis price target lowered to $16 from $20 at H.C. Wainwright